New England Journal of Medicine October 9, 2014 – Ebola/EVD Editorials/Analysis

New England Journal of Medicine
October 9, 2014 Vol. 371 No. 15
http://www.nejm.org/toc/nejm/medical-journal

Perspective
Ebola — A Growing Threat?
H. Feldmann

Brief Report
Emergence of Zaire Ebola Virus Disease in Guinea
Sylvain Baize, Ph.D., Delphine Pannetier, Ph.D., Pharm.D., Lisa Oestereich, M.Sc., Toni Rieger, Ph.D., Lamine Koivogui, Ph.D., N’Faly Magassouba, Ph.D., Barrè Soropogui, M.Sc., Mamadou Saliou Sow, M.D., Sakoba Keïta, M.D., Hilde De Clerck, M.D., Amanda Tiffany, M.P.H., Gemma Dominguez, B.Sc., Mathieu Loua, M.D., Alexis Traoré, M.D., Moussa Kolié, M.D., Emmanuel Roland Malano, M.D., Emmanuel Heleze, M.D., Anne Bocquin, M.Sc., Stephane Mély, M.Sc., Hervé Raoul, Ph.D., Valérie Caro, Ph.D., Dániel Cadar, D.V.M., Ph.D., Martin Gabriel, M.D., Meike Pahlmann, Ph.D., Dennis Tappe, M.D., Jonas Schmidt-Chanasit, M.D., Benido Impouma, M.D., Abdoul Karim Diallo, M.D., Pierre Formenty, D.V.M., M.P.H., Michel Van Herp, M.D., M.P.H., and Stephan Günther, M.D.
N Engl J Med 2014; 371:1418-1425 October 9, 2014 DOI: 10.1056/NEJMoa1404505
In March 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Full-length genome sequencing and phylogenetic analysis showed that EBOV from Guinea forms a separate clade in relationship to the known EBOV strains from the Democratic Republic of Congo and Gabon. Epidemiologic investigation linked the laboratory-confirmed cases with the presumed first fatality of the outbreak in December 2013. This study demonstrates the emergence of a new EBOV strain in Guinea.

Editorial
Ebola — An Ongoing Crisis
Lindsey R. Baden, M.D., Rupa Kanapathipillai, M.B., B.S., M.P.H., D.T.M.&H., Edward W. Campion, M.D., Stephen Morrissey, Ph.D., Eric J. Rubin, M.D., Ph.D., and Jeffrey M. Drazen, M.D.
N Engl J Med 2014; 371:1458-1459 October 9, 2014 DOI: 10.1056/NEJMe1411378
In March 2014, an outbreak of a febrile illness associated with a high case fatality rate was identified in the Guéckédou region of Guinea–Conakry, a remote part of West Africa. An international field investigation was initiated. On April 16, the Journal published a preliminary report identifying the outbreak as due to Ebola virus.1 The initial sequence data showed that the outbreak strain was Zaire ebolavirus, but a strain distinct from those identified in prior outbreaks, such as those in the Democratic Republic of Congo (DRC) and Gabon. In Guinea there appeared to be ongoing human-to-human transmission. Over the next 4 to 8 weeks, the outbreak seemed to be resolving, as over 20 previous outbreaks have, with a substantial decline in new cases. We and many others thought it would soon be over.2

We were wrong. Cases started to appear over the summer, and the number increased exponentially as this viral infection spread more widely in Guinea–Conakry and in Liberia and Sierra Leone.3 Cases associated with travel have been identified in Senegal and Nigeria, and there is evidence of ongoing transmission in Nigeria.4 Recently, Ebola transmission has been identified in the DRC, although molecular data suggest that this event is unrelated to the ongoing West African outbreak.5,6 These molecular data provide the information we need to define important aspects of ongoing transmission dynamics and to guide control strategies. Currently, there is no effective treatment, but human vaccine trials have been initiated.7

As of September 18, 2014, there were 5335 identified cases of Ebola virus disease, with more than 2622 associated deaths, which is more than in all previous Ebola outbreaks combined.4 These numbers are nonetheless likely to be underestimates, given the limitations of case identification, and the fraction of deaths probably underestimates the case fatality rate, because the interval between case identification and death has been just over 2 weeks. Although clinical data remain sparse, it seems likely that effective basic supportive care may make the difference between life and death for an infected patient. Unfortunately, health care workers have been disproportionately affected owing to the tremendous demands of patient care and the difficulty of implementing the infection-control measures required to prevent transmission.8 The Ebola outbreak is having serious adverse effects on travel, commerce, and routine health care, such as care for malaria, which threaten to further disrupt the already precarious conditions in which millions of people in the region live.9

The fear associated with a virulent and potentially deadly contagious infectious disease, which respects neither borders nor social status, has captured the attention of the world. The responders, both local and international, have been dedicated and brave. But far more is needed. It is critical that all members of the global health community — health care workers, scientists, regulators, funders, governments, and local communities — collaborate in responding as rapidly as possible if we are to control this enlarging outbreak. For example, the move by regulators to allow vaccine trials to proceed quickly shows flexibility and good judgment.

We, as a global health care community, must move decisively to bring this dangerous epidemic under control and then to improve the health care systems in the affected region.10 This will require more resources and more health care workers on the front lines (see the Ebola Outbreak page at NEJM.org for volunteer opportunities). It will also require communication and teamwork to win the trust of those in the affected communities. The Journal will continue to report on this unprecedented outbreak with updates on the efforts to control it, the biomedical findings emerging from it, and the difficult stories of those who are suffering through it.